An in vitro Study on Curcumin Delivery by Nano-Micelles for Esophageal Squamous Cell Carcinoma (KYSE-30)

Background: the incidence of esophageal squamous cell carcinoma (escc) is increasing, causing catastrophic health burdens on communities. curcumin has shown promise as a therapeutic agent in the treatment of colon, colorectal, pancreatic, and esophageal cancers but it has very poor bioavailability. the application of nano-carriers as drug delivery systems increases curcumin's bioavailability. cyclin d1 is overexpressed in escc and curcumin may change its expression. methods: in this study, the effect of sinacurcumin®, a novel nano-micelle product containing 80 mg curcumin, on the growth of kyse-30 cells and expression of cyclin d1, was investigated. paclitaxel and carboplatin served as reference drugs. results: nano-curcumin increased cell cytotoxicity, decreased ic50, and down-regulated of cyclin d1. however, treatment of cells with nano-curcumin might result in multidrug resistance. conclusions: nano-curcumin suppressed proliferation of kyse-30 cells and expression of cyclin d1 although its use in combination with other chemotherapeutic agents requires further testing.